Biocartis

03/10/2025

💡 Let's start innovating together!

Biocartis’ mission is to ensure patients and their physicians have access to the right test results at the right time to deliver the right treatment.

Interested to partner with us for a companion diagnostic?

Contact our pharma partnering team 👉 https://www.biocartis.com/en/partnering/partnering-contact?utm_source=facebook&utm_medium=social&utm_campaign=0310_partnering-contact

Connect with us at [email protected] or use the form below to get in touch. Contact us You must have JavaScript enabled to use this form. First name Last name Email Phone Company / Organisation / Institute Country / region Where did you hear about us? Message For information about the processing of...

02/10/2025

🔬 Alfa Healthcare at the Second Annual Pathology Conference – Cairo University

We’re proud to host a session in collaboration with Biocartis, featuring:

🎤 Alessandro Giovenco, MSc., PhD.
Business Lead Oncology – Export Region, Biocartis

With extensive expertise in molecular diagnostics and oncology, Dr. Giovenco will deliver an insightful session:
👉 “NOTHING IS SIMPLE IN ONCOLOGY – NOTHING BUT Idylla”

📅 October 2nd, 2025 | 🕛 12:00 – 12:30 PM (via Zoom)

Join us as we explore how cutting-edge molecular diagnostics are transforming oncology practice and advancing patient care.

Biocartis

02/10/2025

𝗝𝗢𝗜𝗡 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗶𝗻 𝗰𝘆𝘁𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝘀𝗮𝗺𝗽𝗹𝗲 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀
📅 Tuesday 7 October, 11:00 AM (CET)
🗣️ 𝗦𝗽𝗮𝗻𝗶𝘀𝗵
🎤 Dr. Héctor Torres (HUCA), Dr. Aída Molero (H. Río Hortega), Ester Álvaro Sopuerta (Biocartis)
📍 Online, registration required

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
• Use of cytological samples in pathological anatomy
• Study of KRAS in needle wash (serum and Cytolyt™) using the ultra-fast Idylla™ System
• Idylla™ protocols for cytological samples

👉 𝗦𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄: https://register.gotowebinar.com/register/7668493719869061465
𝗖𝗮𝗻’𝘁 𝗷𝗼𝗶𝗻 𝗹𝗶𝘃𝗲? By registering, you will get access to the recording afterwards.

Idylla™ Tests are CE-marked in Europe and are validated for use with FFPE tissue sections. Idylla™ liquid Assays are for Research Use Only (RUO), not for use in diagnostic procedures.
_______________________________________
𝗨𝗡𝗔𝗦𝗘 𝗔 𝗡𝗨𝗘𝗦𝗧𝗥𝗢 𝗦𝗘𝗠𝗜𝗡𝗔𝗥𝗜𝗢 𝗪𝗘𝗕 𝗚𝗥𝗔𝗧𝗨𝗜𝗧𝗢: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗲𝗻 𝗲𝗹 𝗮𝗻𝗮𝗹𝗶𝘀𝗶𝘀 𝗱𝗲 𝗺𝘂𝗲𝘀𝘁𝗿𝗮𝘀 𝗰𝗶𝘁𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝘀
📅 Martes 7 de octubre a las 11:00 h (CET)
🗣️ Español
🎤 Dr. Héctor Torres (HUCA), Dr. Aída Molero (H. Río Hortega), Ester Álvaro Sopuerta (Biocartis)
📍 En línea, con inscripción previa obligatoria

𝗧𝗲𝗺𝗮𝘀 𝗱𝗲𝘀𝘁𝗮𝗰𝗮𝗱𝗼𝘀:
• Utilización de muestras citológicas en anatomía patológica
• Estudio de KRAS en lavado de aguja (suero y Cytolyt™) mediante el sistema ultrarrápido Idylla™
• Protocolos de Idylla™ para muestras citológicas

👉 𝗥𝗲𝘀𝗲𝗿𝘃𝗲 𝘀𝘂 𝗽𝗹𝗮𝘇𝗮 𝗮𝗵𝗼𝗿𝗮: https://register.gotowebinar.com/register/7668493719869061465
¿𝗡𝗼 𝗽𝘂𝗲𝗱𝗲 𝗮𝘀𝗶𝘀𝘁𝗶𝗿 𝗲𝗻 𝗱𝗶𝗿𝗲𝗰𝘁𝗼? Al inscribirse, obtendrá acceso a la grabación posteriormente.

Las pruebas Idylla™ cuentan con marcado CE en Europa y están validadas para su uso con secciones de tejido FFPE. Los ensayos para biopsia líquida Idylla™ son únicamente para uso en investigación (RUO) y no están destinados a ser utilizados en procedimientos diagnósticos

01/10/2025

🎗️October is "Pink Month" or "Breast Cancer Awareness Month", an annual campaign to raise awareness about the impact of breast cancer. Awareness is the first step in the battle against Cancer. Together we rise 🙌❤️

Discover our Breast Cancer Assay Portfolio*: https://www.biocartis.com/en/breast-cancer-assay-portfolio

*For Research Use Only (RUO), not for use in diagnostic procedures.

30/09/2025

📣 𝗚𝗘𝗡𝗢𝗠𝗘𝗪𝗘𝗕 𝗡𝗘𝗪𝗦: 𝗣𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗦𝘆𝘀𝘁𝗲𝗺 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲-𝘁𝗼-𝗔𝗻𝘀𝘄𝗲𝗿 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗖𝗗𝘅 𝗧𝗲𝘀𝘁𝘀
We had the pleasure of talking to GenomeWeb’s Madeleine Johnson about our work in companion diagnostics, following the FDA-approval of our 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁*. This Test is the 𝗳𝗶𝗿𝘀𝘁-𝗲𝘃𝗲𝗿 𝗳𝘂𝗹𝗹𝘆 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱, 𝘀𝗮𝗺𝗽𝗹𝗲-𝘁𝗼-𝗿𝗲𝘀𝘂𝗹𝘁 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗼𝗻 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗳𝗼𝗿 𝗖𝗥𝗖 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀, identifying those eligible for treatment with ± in only 150 minutes 🚀

Roger, W. Michael and Ben also shared insights beyond MSI, including plans to expand the Idylla™ test menu ( , ), advocate for PCR-based cancer panel reimbursement, and drive innovation in precision medicine. They summarized that the fully automated Idylla™ System 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘀 𝗳𝗮𝘀𝘁 𝗿𝗲𝘀𝘂𝗹𝘁𝘀, 𝘄𝗼𝗿𝗸𝘀 𝘄𝗶𝘁𝗵 𝗮 𝗯𝗿𝗼𝗮𝗱 𝗿𝗮𝗻𝗴𝗲 𝗼𝗳 𝘀𝗮𝗺𝗽𝗹𝗲 𝘁𝘆𝗽𝗲𝘀, 𝗮𝗻𝗱 𝗲𝗻𝗮𝗯𝗹𝗲𝘀 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 - benefits that improve decision-making for clinicians and patients alike 🤲

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: https://www.genomeweb.com/.../biocartis-positioning...
👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁: https://www.biocartis.com/.../idylla.../idylla-cdx-msi-test

*Approved in the US under P250005.

29/09/2025

🚀 NOW AVAILABLE: 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄-𝐏𝐎𝐋𝐃𝟏 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐬𝐬𝐚𝐲*
✅ Molecular classification of samples in ~ 95 min.
✅ Covers 99% of the known pathogenic & mutations
✅ Achieved 98.2% accuracy with 450+ endometrial cancer samples (Barault et al., 2024)
✅ Fit for use on small biopsies & directly from 1 FFPE tissue section
✅ No need for sample batching
✅ Straightforward results reporting

👉 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay?utm_source=facebook&utm_medium=social&utm_campaign=2909_idylla-pole-pold1-mutation-assay

*For Research Use Only (RUO), not for use in diagnostic procedures.
Barault, L. et al. (2024). The Idylla™ POLE Mutation Assay, A New Tool For Direct Mutation Detection From FFPE Tissue. AMP 2024 Annual Meeting

29/09/2025

Cedric has been busy at the #𝗡𝗦𝗛 𝗛𝗶𝘀𝘁𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗖𝗼𝗻𝘃𝗲𝗻𝘁𝗶𝗼𝗻, introducing folks to how Idylla™ can deliver molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀! Stop by today or tomorrow for a live demo!
🗓️ 26 - 30 September |🗺️ Long Beach, CA, US

👉 𝗕𝗼𝗼𝗸 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en-US/news-events/events/nsh-convention-2025
👉 𝗠𝗲𝗲𝘁 𝗜𝗱𝘆𝗹𝗹𝗮™: https://www.biocartis.com/en-US/meet-idylla

26/09/2025

💡 Early detection and prompt treatment are crucial for lung cancer patients
Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*.

IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️

Learn more 👉🏻https://www.biocartis.com/sites/default/files/2025-06/idylla_first-line_lung_1l_-_leaflet_-_may2025.pdf


*Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

26/09/2025

✨ Day 1 was a success, now Ester and Marta are back for day 2 at in beautiful Porto! Come find us and say hi! 👋

👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗻𝗼𝘄: https://www.biocartis.com/en/meet-idylla

25/09/2025

✍ 𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀!
We're excited to be at the Annual Congress of Asian Society of Digital Pathology (ASDP) 2025 in Mumbai, India (10–12 October)!

📍 Find us at 𝗯𝗼𝗼𝘁𝗵 𝟬𝟰, where Mashood & Alessandro show you how Idylla™ can deliver 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗶𝗻 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀! ⏱️
👉 Book your meeting now: https://www.biocartis.com/en/news-events/events/asdp-2025

Looking forward to seeing you there! 👋

25/09/2025

✨ Yesterday, our very own Chris van Haag took the stage at 𝗪𝗼𝗿𝗹𝗱 𝗖𝗕 & 𝗖𝗗𝘅 to share how Biocartis is redefining companion diagnostics.

One of the highlights he touched upon, was our latest breakthrough: the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁! The first-ever fully automated, sample-to-result companion diagnostic for CRC patients 🚀
👉 Learn more: https://lnkd.in/e8r9Nhry

A big thank you to everyone who joined the session - your engagement and interest inspire us to keep pushing the boundaries of innovation 🙌

𝗔𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗪𝗼𝗿𝗹𝗱 𝗖𝗕 & 𝗖𝗗𝘅 𝗶𝗻 𝗕𝗼𝘀𝘁𝗼𝗻, 𝗨𝗦 (𝟮𝟮–𝟮𝟱 𝗦𝗲𝗽𝘁)?
Come by 𝗯𝗼𝗼𝘁𝗵 𝟯𝟴 and meet Lei, Lisa and Chris. They’ll show you how Idylla™ can deliver molecular biomarker results in only 3 hours ⏱️

24/09/2025

🤘 𝗛𝗮𝘃𝗶𝗻𝗴 𝗮 𝗯𝗹𝗮𝘀𝘁 𝗮𝘁 #𝗦𝗙𝗘𝟮𝟬𝟮𝟱!
Come visit Corinne, Julie and David at the SFE Congress in Lille, France (24-26 September)!

👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™: https://www.biocartis.com/en/research/research-assays/idylla-thyroidprintr-assay-0